Risk Stratification for ADLTA-RVC in Children and Young Adolescents

It's too early at the moment to be able to draw any conclusions in terms of risk stratification, but I think the key first step is that it studies really for the first time a pediatric ARVC population. As novel therapies are emerging, as the promise of disease modulation emerges, it becomes ever more important for us to systematically include children and young adolescents in our cohort studies. So how does disease evolve? How does it develop? And only then will we be able to truly understand the disease process. We would welcome you now to the publication of our last paper on ADLTA-RVC.